Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
American Diabetes Association (ADA) 78th Scientific Sessions
June 22 - 26, 2018; Orlando, Florida
June 22 - 26, 2018Orlando, Florida
ADA 2018Asian Indians Up Diabetes Risk by Adopting Poor LifestyleProviding culturally friendly diet, education, and physical activity programs may promote lifestyle changes and prevent diabetes in this high-risk group of Asian Indian Americans, say researchers.
Top News From ADA 2018: SlideshowNew trial results in type 1 and type 2 diabetes and glucose-sensing technology featured prominently at this year's meeting.
CANVAS: Experts Spar on Canagliflozin Risk/Benefit in DiabetesSome see the newly revealed cardiovascular benefits as rendering canagliflozin essentially "interchangeable" with empagliflozin,
while others view the amputation signal as a deal breaker.
Medscape Medical News, Jun 16, 2017
CV-Outcomes Trials in Diabetes Must Drive Guideline ChangeOn the eve of the results of another large CV-outcomes trial with a type 2 diabetes drug, Steve Nissen told the ADA meeting
why these studies are so important and must drive change in clinical practice.
Medscape Medical News, Jun 12, 2017
A Perfect Twitter Storm: Why Is the ADA So Anti-Social Media?A big row has erupted on Twitter at the ADA meeting, where organizers are politely requesting that users delete tweets containing
pictures of slides. Many refused and called on the ADA to change this policy.
SGLT1/2 Inhibitor Sotagliflozin 'Encouraging' in Type 1 DiabetesThe investigational, oral agent sotagliflozin, a first-in-class, oral dual inhibitor of both SGLT1 and SGLT2, is in phase
3 trials in type 1 diabetes; results are promising but there are some caveats.